# Surgery Partners, Inc. (SGRY) Investor Outlook: Evaluating a 42% Upside Potential in the Healthcare Sector

- Link: https://www.directorstalkinterviews.com/surgery-partners-inc-sgry-investor-outlook-evaluating-a-42-upside-potential-in-the-healthcare-sector/4121206486
- Published: 2025-07-08T10:47:26+01:00
- Author: Madison Wilson

Surgery Partners, Inc. (NASDAQ: SGRY) has been steadily carving out a significant
niche in the healthcare sector, specifically within the medical care facilities 
industry. With a market capitalization of $2.82 billion, this U.S.-based company
operates a network of surgical facilities and ancillary services that cater to a
wide range of specialties, including orthopedics, ophthalmology, gastroenterology,
and more. Founded in 2004 and headquartered in Brentwood, Tennessee, Surgery Partners
offers both single- and multi-specialty facilities, positioning itself as a versatile
player in the non-emergency surgical procedures landscape.

Currently trading at $22.03, Surgery Partners’ stock price has experienced a minor
dip of 0.12 USD (-0.01%). The 52-week price range of $19.30 to $33.69 highlights
some volatility, yet presents an intriguing opportunity for investors willing to
engage with the healthcare sector’s dynamic nature.

The valuation metrics for Surgery Partners reveal a forward P/E ratio of 20.42, 
though several other key figures such as the trailing P/E, PEG, and Price/Book ratios
are unavailable, indicating potential volatility and uncertainty in earnings consistency.
Despite these gaps, the company’s revenue growth of 8.20% underscores its ability
to expand and capture more market share in a competitive industry.

Despite reporting a negative earnings per share (EPS) of -1.53 and a slightly negative
return on equity of -0.35%, Surgery Partners demonstrates robust operational efficiency
with a free cash flow of $142.6 million. This liquidity can be a strong foundation
for future investments in expanding its facilities and services.

A significant draw for investors is the analyst ratings and their associated price
targets. With 9 buy ratings against 3 holds and no sell recommendations, the sentiment
around Surgery Partners is largely optimistic. The average target price of $31.36
suggests a potential upside of approximately 42.37%, a compelling figure for growth-
oriented investors. The target price range between $24.00 and $36.00 provides a 
broad spectrum of anticipated performance, aligning with the company’s growth potential.

From a technical analysis perspective, Surgery Partners holds a 50-day moving average
of $22.50 and a 200-day moving average of $24.45. The current RSI (Relative Strength
Index) stands at 79.72, indicating that the stock is in overbought territory, which
could suggest a potential price correction. The MACD (Moving Average Convergence
Divergence) of -0.17, with a signal line of -0.28, further supports a cautious approach
in the short term.

Surgery Partners does not currently offer dividends, maintaining a payout ratio 
of 0.00%. This reinvestment strategy could appeal to investors focused on long-term
capital appreciation rather than immediate income.

In summary, Surgery Partners, Inc. presents a mixed yet intriguing investment case.
The combination of solid revenue growth, a significant free cash flow, and a positive
outlook from analysts supports the potential for substantial upside. However, prospective
investors should carefully weigh these growth prospects against the current valuation
uncertainties and technical indicators suggesting potential near-term volatility.
For those with a long-term horizon and a risk-tolerant portfolio, Surgery Partners
could offer rewarding exposure to the healthcare sector’s evolving landscape.

Share on: